Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of disodium dimercaptosuccinate in preparation of medicine for treating or preventing viral hepatitis

A dimercaptobutane disodium, viral hepatitis technology, applied in antiviral agents, drug combinations, pharmaceutical formulations, etc., to achieve excellent pharmacokinetic properties, removal of hepatitis B virus, and good druggability.

Pending Publication Date: 2021-09-28
HOLY HAID LAB CORP
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] At present, the research on the indications of disodium dimercapto is mainly aimed at its detoxification application, and there is no research report on its use in the treatment or prevention of viral hepatitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of disodium dimercaptosuccinate in preparation of medicine for treating or preventing viral hepatitis
  • Application of disodium dimercaptosuccinate in preparation of medicine for treating or preventing viral hepatitis
  • Application of disodium dimercaptosuccinate in preparation of medicine for treating or preventing viral hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Embodiment 1-apply HepG2-NTCP cell to evaluate the in vitro anti-HBV activity of test compound dimercapto disodium

[0068] Compound preparation method is as follows:

[0069] Take the preparation of 10mM concentration as an example, the volume of solvent DMSO (μl) = sample mass (mg) × purity ÷ molecular weight ÷ 10 × 10 6

[0070] Control compounds included ETV (lot number: P1214012; 99.0% purity), purchased from Shanghai Titan Technology Co., Ltd.; and RG7834 (RG7834, also known as RO 7020322, is a highly selective and orally bioavailable HBV inhibitor, potent Inhibition of HBV antigens (HBsAg and HBeAg) and HBV DNA. Batch number: ET25747-14-P1; 99.5% purity), obtained from Shanghai WuXi Kangde New Drug Development Co., Ltd. The stock solutions of the above reference compounds were all at a concentration of 20 mM and stored at -20°C.

[0071] Table 1: Major Reagents and Cell Viruses

[0072]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of disodium dimercaptosuccinate in preparation of a medicine for treating or preventing viral hepatitis. Specifically, the invention provides application of the disodium dimercaptosuccinate in preparation of the medicine for treating or preventing viral hepatitis, and preferably, the viral hepatitis is hepatitis B. The invention also provides a pharmaceutical composition for treating or preventing viral hepatitis, and the pharmaceutical composition comprises the disodium dimercaptosuccinate, the derivative of the disodium dimercaptosuccinate and optionally one or more additional therapeutic agents or prophylactic agents, and a pharmaceutically acceptable carrier.

Description

technical field [0001] The invention relates to the technical field of antiviral drugs, in particular to a pharmaceutical composition for treating or preventing viral hepatitis and its application. Background technique [0002] Human hepatitis B virus (HBV) infection is an important public health problem worldwide. After acute hepatitis B virus infection, about 8% still develop into chronic hepatitis B infection, and persistent HBV infection will lead to liver cirrhosis and even liver cancer. my country is a big country with hepatitis B, and there are nearly 130 million hepatitis B virus carriers, accounting for about 9% of the total population. Although the new hepatitis B infection rate has been effectively controlled with the widespread popularization of hepatitis B vaccine, the population base of hepatitis B carriers is large, and the prevention and treatment of hepatitis B has become the top priority of public health problems in my country. Hepatitis B transmission is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/194A61K45/06A61K31/4045A61K31/522A61K31/675A61K38/21A61K31/426A61K9/20A61K9/48A61P1/16A61P31/20A61P31/14
CPCA61K31/194A61K45/06A61K31/4045A61K31/522A61K31/675A61K38/21A61K31/426A61K9/20A61K9/48A61P1/16A61P31/20A61P31/14
Inventor 李瑛颖陈明键仇思念
Owner HOLY HAID LAB CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com